Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 19846 AL 19860

Generic and disease-specific measures of quality of life in patients with mild Alzheimer's disease

Bhattacharya S, Vogel A, Hansen ML, Waldorff FB, Waldemar G.

Dement Geriatr Cogn Disord. 2010;30(4):327-33. doi: 10.1159/000320588. Epub 2010 Oct 2.

Developmental exposure to lead and late life abnormalities of nervous system

Basha R, Reddy GR.

Indian J Exp Biol. 2010 Jul;48(7):636-41.

Phenserine efficacy in Alzheimer's disease

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment

Sabbagh MN, Malek-Ahmadi M, Kataria R, Belden CM, Connor DJ, Pearson C, Jacobson S, Davis K, Yaari R, Singh U.

J Alzheimers Dis. 2010;22(3):1015-21. doi: 10.3233/JAD-2010-101185.

Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain

Ariga T, Yanagisawa M, Wakade C, Ando S, Buccafusco JJ, McDonald MP, Yu RK.

ASN Neuro. 2010 Oct 4;2(4):e00044. doi: 10.1042/AN20100021.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression

Di Domenico F, Owen JB, Sultana R, Sowell RA, Perluigi M, Cini C, Cai J, Pierce WM, Butterfield DA.

J Neurosci Res. 2010 Dec;88(16):3566-77. doi: 10.1002/jnr.22528. Epub 2010 Oct 8.

Beclin 1 complex in autophagy and Alzheimer disease

Jaeger PA, Wyss-Coray T.

Arch Neurol. 2010 Oct;67(10):1181-4. doi: 10.1001/archneurol.2010.258.

Reduced precuneus deactivation during object naming in patients with mild cognitive impairment, Alzheimer's disease, and frontotemporal lobar degeneration

Frings L, Dressel K, Abel S, Saur D, Kümmerer D, Mader I, Weiller C, Hüll M.

Dement Geriatr Cogn Disord. 2010;30(4):334-43. doi: 10.1159/000320991. Epub 2010 Oct 11.

Investigational medications for treatment of patients with Alzheimer disease

Potter PE.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.

Recruitment of subjects into clinical trials for Alzheimer disease

Knebl JA, Patki D.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.

Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease

Butterfield DA, Reed T, Sultana R.

Free Radic Res. 2011 Jan;45(1):59-72. doi: 10.3109/10715762.2010.520014. Epub 2010 Oct 13.

Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?

Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.

Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.

Novel drug targets based on metallobiology of Alzheimer's disease

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.

Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias